CPL207-280, a Potent and Safe GPR40 Agonist for the treatment of Type 2 Diabetes

被引：2
|
作者：
Bazydlo-Guzenda, Katarzyna
Buda, Pawel
Kozlowska, Izabela
Mach, Mateusz
Teska-Kaminska, Malgorzata
Stelmach, Filip
Wasinska-Kalwa, Malgorzata
Galazka, Kinga
Dubiel, Krzysztof K.
Pieczykolan, Jerzy S.
Wieczorek, Maciej
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-2333-PUB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2333-PUB
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Variants in the GPR40 gene and association with type 2 diabetes
    Kalis, M.
    Leveen, P.
    Lyssenko, V.
    Almgren, P.
    Olde, B.
    Owman, C.
    Groop, L.
    Cilio, C. M.
    DIABETOLOGIA, 2006, 49 : 37 - 37
  • [22] GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit
    Mancini, A. D.
    Poitout, V.
    DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 622 - 629
  • [23] Discovery and development of CPL207280 as new GPR40/FFA1 agonist
    Mach, Mateusz
    Bazydlo-Guzenda, Katarzyna
    Buda, Pawel
    Matloka, Mikolaj
    Dzida, Radoslaw
    Stelmach, Filip
    Galazka, Kinga
    Wasinska-Kalwa, Malgorzata
    Smuga, Damian
    Holowinska, Dagmara
    Dawid, Urszula
    Gurba-Bryskiewicz, Lidia
    Wisniewski, Krzysztof
    Dubiel, Krzysztof
    Pieczykolan, Jerzy
    Wieczorek, Maciej
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 226
  • [24] Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes
    Christiansen, Elisabeth
    Hansen, Steffen V. F.
    Urban, Christian
    Hudson, Brian D.
    Wargent, Edward T.
    Grundmann, Manuel
    Jenkins, Laura
    Zaibi, Mohamed
    Stocker, Claire J.
    Ullrich, Susanne
    Kostenis, Evi
    Kassack, Matthias U.
    Milligan, Graeme
    Cawthorne, Michael A.
    Ulven, Trond
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (05): : 441 - 445
  • [25] AMG 837: A potent, orally bioavailable, partial allosteric agonist of GPR40
    Houze, Jonathan B.
    Zhu, Liusheng
    Sun, Ying
    Akerman, Michelle
    Qiu, Wei
    Zhang, Alex J.
    Sharma, Rajiv
    Schmitt, Michael
    Wang, Yingcai
    Liu, Jiwen
    Medina, Julio C.
    Reagan, Jeff D.
    Luo, Jian
    Tonn, George
    Zhang, Jane
    Guo, Qi
    Swaminath, Gayathri
    Lu, Jenny Y. -L.
    Chen, Michael
    Lopez, Edwin
    Nguyen, Kathy
    Yang, Li
    Tang, Liang
    Tian, Hui
    Shuttleworth, Steven J.
    Lin, Daniel C. -H.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [26] Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist
    Takano, Rieko
    Yoshida, Masao
    Inoue, Masahiro
    Honda, Takeshi
    Nakashima, Ryutaro
    Matsumoto, Koji
    Yano, Tatsuya
    Ogata, Tsuneaki
    Watanabe, Nobuaki
    Hirouchi, Masakazu
    Yoneyama, Tomoko
    Ito, Shuichiro
    Toda, Narihiro
    ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (03): : 266 - 270
  • [27] Advances in Small-Molecule GPR40 Agonists for Treatment of Type 2 Diabetes Mellitus
    Li, He
    Long, Yaqiu
    CHINESE JOURNAL OF ORGANIC CHEMISTRY, 2016, 36 (04) : 736 - 743
  • [28] GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space
    Chen, Cheng
    Li, He
    Long, Ya-Qiu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (23) : 5603 - 5612
  • [29] Discovery of 5-substituted-2,4-oxazolidinedionesas potent GPR40 agonists for treatment of type II diabetes
    Lin, Songnian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [30] Vincamine as a GPR40 agonist improves glucose homeostasis in type 2 diabetic mice
    Du, Te
    Yang, Liu
    Xu, Xu
    Shi, Xiaofan
    Xu, Xin
    Lu, Jian
    Lv, Jianlu
    Huang, Xi
    Chen, Jing
    Wang, Heyao
    Ye, Jiming
    Hu, Lihong
    Shen, Xu
    JOURNAL OF ENDOCRINOLOGY, 2019, 240 (02) : 195 - 214
12345